Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy - Overview
Optic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Biozeus Pharmaceutical SA
jCyte Inc
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Optic Neuropathy - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
BZ-371 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Therapy for Glaucoma and Optic Neuropathies - Drug Profile
Product Description
Mechanism Of Action
CSIC-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fab-3H4 - Drug Profile
Product Description
Mechanism Of Action
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
Protein for Optic Neuropathy and Retil Degeneration - Drug Profile
Product Description
Mechanism Of Action
History of Events
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting
Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in Chi for a Pivotal Clinical Trial with a siR Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote ION Study Steps-Up Recruitment for Phase II/III Research on ?Stroke of the Eye’
Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siR candidate QPI-1007
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of Ri-Based Therapeutic QPI-1007 for Eye Indications
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in ION
Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siR Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Optic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Optic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Optic Neuropathy - Pipeline by Astellas Pharma Inc, 2022
Optic Neuropathy - Pipeline by Biozeus Pharmaceutical SA, 2022
Optic Neuropathy - Pipeline by jCyte Inc, 2022
Optic Neuropathy - Pipeline by Neurizon Pharma GBR, 2022
Optic Neuropathy - Pipeline by PharmatrophiX Inc, 2022
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, 2022
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Optic Neuropathy - Dormant Projects, 2022
Optic Neuropathy - Discontinued Products, 2022